Phase I trials of amonafide as monotherapy and in combination with cytarabine in patients with poor-risk acute myeloid leukemia

被引：8
|
作者：
Allen, Steven L. [1 ]
Kolitz, Jonathan E. [2 ]
Lundberg, Ante S. [3 ]
Bennett, John M. [4 ]
Capizzi, Robert L. [3 ]
Budman, Daniel R. [2 ]
机构：
[1] N Shore Univ Hosp, Albert Einstein Coll Med, Monter Canc Ctr, Lake Success, NY 11042 USA
[2] New York Univ, N Shore Univ Hosp, Monter Canc Ctr, Sch Med, Lake Success, NY USA
[3] Antisoma, Cambridge, MA USA
[4] Univ Rochester, James P Wilmot Canc Ctr, Rochester, NY USA
来源：
LEUKEMIA RESEARCH | 2010年 / 34卷 / 04期
关键词：
AML; Phase I; P-glycoprotein; Pgp; Multidrug resistance; SOUTHWEST-ONCOLOGY-GROUP; MULTIDRUG-RESISTANCE; P-GLYCOPROTEIN; MYELODYSPLASTIC-SYNDROME; POSTREMISSION THERAPY; ANTITUMOR-ACTIVITY; ELDERLY-PATIENTS; GROUP-B; CANCER; INDUCTION;
D O I：
10.1016/j.leukres.2009.07.038
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Amonafide-L-malate ( amonafide) is a unique DNA intercalator that maintains activity in the presence of MDR mechanisms, a frequent cause of treatment-failure in secondary AML. 43 patients with relapsed/refractory or secondary AML or CML blast crisis were enrolled into two phase I dose-escalation studies investigating amonafide as monotherapy or in combination with cytarabine. 3/17 patients in the monotherapy trial and 10/26 patients in the combination trial achieved a complete remission. Between both trials responses occurred in 9/20 patients with secondary AML. Both trials demonstrated an acceptable safety profile and significant antileukemic activity in patients with poor-risk AML, especially those with secondary AML. (C) 2009 Elsevier Ltd. All rights reserved.
引用
收藏
页码：487 / 491
页数：5
相关论文
共 50 条
  • [41] Volasertib as a monotherapy or in combination with azacitidine in patients with myelodysplastic syndrome, chronic myelomonocytic leukemia, or acute myeloid leukemia: summary of three phase I studies
    Platzbecker, Uwe
    Chromik, Joerg
    Kroenke, Jan
    Handa, Hiroshi
    Strickland, Stephen
    Miyazaki, Yasushi
    Wermke, Martin
    Sakamoto, Wataru
    Tachibana, Yoshifumi
    Taube, Tillmann
    Germing, Ulrich
    BMC CANCER, 2022, 22 (01)
  • [42] Volasertib as a monotherapy or in combination with azacitidine in patients with myelodysplastic syndrome, chronic myelomonocytic leukemia, or acute myeloid leukemia: summary of three phase I studies
    Uwe Platzbecker
    Joerg Chromik
    Jan Krönke
    Hiroshi Handa
    Stephen Strickland
    Yasushi Miyazaki
    Martin Wermke
    Wataru Sakamoto
    Yoshifumi Tachibana
    Tillmann Taube
    Ulrich Germing
    BMC Cancer, 22
  • [43] Combination of topotecan with cytarabine or etoposide in patients with refractory or relapsed acute myeloid leukemia: Results of a randomized phase I/II study.
    Vey, N
    Kantarjian, H
    Beran, M
    O'Brien, S
    Cortes, J
    Giles, FJ
    Koller, C
    Estey, E
    BLOOD, 1998, 92 (10) : 235A - 235A
  • [44] Phase I study of alvocidib plus cytarabine/mitoxantrone or cytarabine/daunorubicin for acute myeloid leukemia in Japan
    Ikezoe, Takayuki
    Ando, Kiyoshi
    Onozawa, Masahiro
    Yamane, Takahisa
    Hosono, Naoko
    Morita, Yasuyoshi
    Kiguchi, Toru
    Iwasaki, Hiromi
    Miyamoto, Toshihiro
    Matsubara, Keisuke
    Sugimoto, Saori
    Miyazaki, Yasushi
    Kizaki, Masahiro
    Akashi, Koichi
    CANCER SCIENCE, 2022, 113 (12) : 4258 - 4266
  • [45] Outcome of Patients with Acute Myeloid Leukemia Treated with Salvage High-Dose Cytarabine Monotherapy
    Canaani, Jonathan
    Luskin, Marlise R.
    Loren, Alison
    Timlin, Colleen
    Mangan, James
    Hexner, Elizabeth O.
    Frey, Noelle V.
    Porter, David L.
    Stadtmauer, Edward A.
    Luger, Selina
    BLOOD, 2015, 126 (23)
  • [46] A Phase I Study of Fludarabine, Cytarabine, and Oxaliplatin Therapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia
    Tsimberidou, Apostolia Maria
    Keating, Michael J.
    Jabbour, Elias J.
    Ravandi-Kashani, Farhad
    O'Brien, Susan
    Estey, Elihu
    Bekele, Neby
    Plunkett, William K., Jr.
    Kantarjian, Hagop
    Borthakur, Gautam
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2014, 14 (05): : 395 - 400
  • [47] Fludarabine, arabinosyl cytosine and idarubicin (FLAI) for remission induction in poor-risk acute myeloid leukemia
    Russo, D
    Pricolo, G
    Michieli, M
    Michelutti, A
    Raspadori, D
    Bertone, A
    Marin, L
    Pierri, I
    Bucalossi, A
    Zuffa, E
    De Vivo, A
    Mazza, P
    Gobbi, M
    Lauria, F
    Zaccaria, A
    Baccarani, M
    LEUKEMIA & LYMPHOMA, 2001, 40 (3-4) : 335 - 343
  • [48] Combination of HDCT with MIBG I Radiotherapy in Poor-Risk Neuroblastoma Patients Treatment
    Daylidite, V.
    Mentkevich, G.
    Dolgopolov, I.
    Subbotina, N.
    Boyarshinov, V.
    PEDIATRIC BLOOD & CANCER, 2019, 66 : S605 - S605
  • [49] Combination of liposomal daunorubicin, fludarabine and cytarabine (FLAD) in patients with poor risk acute leukemia: Preliminary results.
    Pierri, I
    Miglino, M
    Clavio, M
    Venturino, C
    Quintino, S
    Galbusera, V
    Garrone, A
    Varaldo, R
    Gatto, S
    Beltrami, G
    Ballerini, F
    Canepa, L
    Gobbi, M
    BLOOD, 2001, 98 (11) : 219B - 219B
  • [50] Twice Daily Fludarabine and Cytarabine Combination Is Effective in Patients with Relapsed/Refractory Acute Myeloid Leukemia, High-Risk Myelodysplastic Syndromes, and Blast Phase Chronic Myeloid Leukemia
    Daver, Naval
    Kantarjian, Hagop M.
    Garcia-Manero, Guillermo
    Cortes, Jorge E.
    Ravandi, Farhad
    Plunkett, William
    Gandhi, Varsha
    Faderl, Stefan
    O'Brien, Susan
    Borthakur, Gautam
    Kadia, Tapan
    Burger, Jan A.
    Konopleva, Marina
    Brandt, Mark
    Huang, Xuelin
    Jabbour, Elias
    BLOOD, 2011, 118 (21) : 1550 - 1550
12345